Savara Inc

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate

box

:

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

Dear Fellow Stockholder,

On behalf of the Board of Directors, it is my pleasure to invite you to attend the Savara Inc. 2026 Annual Meeting of Stockholders, to be held on June 4, 2026 at 3:00 p.m. Eastern Time via live webcast atwww.virtualshareholdermeeting.com/SVRA2026. The attached Notice of Annual Meeting and Proxy Statement contains important information about the meeting and matters for your consideration. Your vote is important, and regardless of whether you plan to attend the meeting, I encourage you to review the material carefully and submit your proxy.

We are at a pivotal time as we work to bring our investigational therapy, molgramostim inhalation solution (MOLBREEVI*), to market to address the significant unmet need in autoimmune pulmonary alveolar proteinosis (autoimmune PAP), a rare and debilitating lung disease. Marketing applications for MOLBREEVI for the treatment of autoimmune PAP are currently under review by regulatory authorities in the U.S., EU, and UK. The U.S. Food & Drug Administration (FDA) is reviewing the MOLBREEVI Biologics License Application under Priority Review, with an Action Date of November 22, 2026. The MOLBREEVI Marketing Authorisation Application (MAA) is being reviewed in the EU with a decision expected in Q1 2027, and in the UK with a decision expected in Q4 2026. As we prepare for a potential commercial launch of MOLBREEVI, we have taken steps to ensure we are on strong financial footing by completing a $149.5 million equity financing, entering into a $75 million royalty funding agreement with RTW to support the potential launch, and amending our debt facility to provide for up to $75 million in additional debt funding upon FDA approval.

Over the years, we have been guided by the unwavering purpose of dramatically improving the standard of care for people living with autoimmune PAP while creating long-term value for our stockholders. This purpose has not, and will not, change as we get closer to a potential approval in the U.S. and transition to a commercial company.

Thank you for your continued support.

Sincerely,

/s/ Matthew Pauls

Matthew Pauls

Chair of the Board of Directors & Chief Executive Officer

*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

To Be Held on June 4, 2026

The 2026 Annual Meeting of Stockholders of Savara Inc. (the “Annual Meeting”) will be held virtually via live webcast atwww.virtualshareholdermeeting.com/SVRA2026 on June 4, 2026 at 3:00 p.m. Eastern Time. The meeting is being held for the following purposes, as more fully described in the proxy statement accompanying this notice:

1. To elect six directors to hold office until the next annual meeting of stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal;

2. To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from 300,000,000 to 600,000,000;

3. To approve the amendment of the Savara Inc. 2024 Omnibus Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 18,900,000;

4. To ratify the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;

5. To approve, on an advisory basis, the compensation of our named executives; and

6. To transact such other business as may properly come before the Annual Meeting and any adjournment or postponement thereof.

Only stockholders of record at the close of business on April 6, 2026 will be entitled to notice of, and to vote at, the Annual Meeting and any adjournment or postponement thereof. A list of stockholders entitled to vote at the Annual Meeting will be available for inspection by any stockholder for any purpose relating to the meeting during ordinary business hours at our corporate offices located at One Summit Square, 1717 Langhorne Newtown Rd., Suite 300, Langhorne, PA 19047 for ten days prior to the Annual Meeting, and will also be available for inspection at the Annual Meeting.

Your vote is important. Whether or not you plan to attend the Annual Meeting, and no matter how many shares you own, please vote as promptly as possible. This will help to ensure the presence of a quorum at the Annual Meeting and save us additional proxy solicitation costs.

All stockholders are cordially invited to attend the Annual Meeting.

By Order of the Board of Directors,

/s/ Matthew Pauls

Matthew Pauls

Chair of the Board of Directors & Chief Executive Officer

Langhorne, PA

Important Notice Regarding the Availability of Proxy Materials for the Stockholders’ Meeting To Be Held on June 4, 2026. This notice of Annual Meeting, the proxy statement for the Annual Meeting and our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 are available at www.proxyvote.com.